To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:261 Issue:1 Number:4 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
RCT
ACE Report #14743
Ace Report Cover Shoulder & Elbow

SABER-Bupivacaine for Post-Operative Pain and Opioid Consumption for Subacromial Decompression


How to Cite

OrthoEvidence. SABER-Bupivacaine for Post-Operative Pain and Opioid Consumption for Subacromial Decompression. ACE Report. 2022;261(1):4. Available from: https://myorthoevidence.com/AceReport/Report/14743

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

SABER-Bupivacaine Reduces Postoperative Pain and Opioid Consumption After Arthroscopic Subacromial Decompression: A Randomized, Placebo-Controlled Trial

J Am Acad Orthop Surg Glob Res Rev . 2022 May 1;6(5).

Contributing Authors:
A Ekelund A Peredistijs J Grohs J Meisner N Verity S Rasmussen

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

One hundred and seven patients undergoing an arthroscopic subacromial decompression (ASD) surgery were randomized (in a 2:1:1 ratio) to receive either sucrose acetate isobutyrate extended-release (SABER) bupivacaine (n=53), SABER-placebo (n=25), or bupivacaine HCl (n=29) to minimize post-operative pain and opioid consumption. The primary outcomes of this trial were to assess pain scores and analge...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.